Results 81 to 90 of about 1,334 (146)

Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Berenike Cornelia Kunzmann, Alexandra Stefanie Schweig, Karl Ulrich Bartz-Schmidt, Bianka Sobolewska University Eye Hospital, Centre for Ophthalmology, University of Tuebingen, Tuebingen, GermanyCorrespondence: Berenike Cornelia Kunzmann, University Eye ...
Kunzmann BC, Schweig AS, Bartz-Schmidt KU, Sobolewska B   +3 more
doaj  

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

Early anatomical outcomes of faricimab vs aflibercept 2 mg in treatment-naïve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: A head-to-head comparative study in Taiwan. [PDF]

J Chin Med Assoc
Yang CC, Weng CC, Chou YB, Huang YM, Lin TC, Chen SJ, Hwang DK.   +6 more
europepmc   +1 more source

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. [PDF]

Int J Retina Vitreous
Ruiz-Medrano J, Pana I, García-Zamora M, Flores-Moreno I, Puertas M, Ruiz-Moreno JM.   +5 more
europepmc   +1 more source

Neovascular age-related macular degeneration complicated by large submacular hemorrhage managed with faricimab monotherapy. [PDF]

Int J Retina Vitreous
Lim J, Cho H, Ramkumar H, Adrean SD.
europepmc   +1 more source

Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool. [PDF]

Int J Retina Vitreous
Barbosa M, Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Barry MP, Ambresin A.   +6 more
europepmc   +1 more source

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. [PDF]

Retina
Jaffe GJ, Deák G, Gibson K, Khurana RN, Nudleman E, Ogura Y, Schmidt-Erfurth U, Wang T, Westenskow PD, Wong D, Yiu G, Willis JR.   +11 more
europepmc   +1 more source

Faricimab for retinal vein occlusion: a review of current evidence and future perspectives. [PDF]

Front Pharmacol
Jing Y, Li D.
europepmc   +1 more source

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. [PDF]

Eye (Lond)
Peto T, Pearce I, Talks J, de Salvo G, Patel PJ, de Silva SR, Gale RP, Sivaprasad S, Varma D, Reynolds R, Bailey C, Downey L, Kiire C, Chi GC, Dodds M, James N, Downey AK, Dayal P.   +17 more
europepmc   +1 more source

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report. [PDF]

Am J Case Rep
Sano H, Yanai R, Mitamura Y.
europepmc   +1 more source